Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Delcath Systems Inc DCTH.OQ reported quarterly adjusted earnings of 7 cents per share for the quarter ended June 30, identical to the same quarter last year. The mean expectation of six analysts for the quarter was for a loss of 9 cents per share. Wall Street expected results to range from -16 cents to -5 cents per share.
Revenue rose 20.6% to $29.13 million from a year ago; analysts expected $26.26 million.
Delcath Systems Inc's reported EPS for the quarter was 7 cents.
The company reported quarterly net income of $2.67 million.
Delcath Systems Inc shares had risen by 0.3% this quarter and gained 25.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 3.3% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for Delcath Systems Inc is $21.50, about 41.3% above its last closing price of $12.63
This summary was machine generated from LSEG data August 6 at 02:25 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.09 | 0.07 | Beat |
Mar. 31 2026 | -0.09 | -0.03 | Beat |
Dec. 31 2025 | -0.06 | -0.05 | Beat |
Sep. 30 2025 | 0.02 | 0.02 | Met |
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Highlights Clinical Program Presentations At Esmo Congress 2026 And Independent Data On Percutaneous Hepatic Perfusion In Liver-Dominant Metastatic Uveal Melanoma
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule
Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Delcath Systems Q2 revenue rises, beats estimates
Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview